SCHEMBL3548433

SCHEMBL3548433

CCNC(=O)c1nc2c(s1)C(=O)C=C(NCCN(C)C)C2=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.64
CDC25B P30305 2/20 0.64
CDC25C P30307 2/20 0.64
MALT1 Q9UDY8 1/20 0.41
CDK4 P11802 9/20 0.36
MEN1 O00255 1/20 0.35
THRB P10828 1/20 0.35
CCND1 P24385 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
KMT5A Q9NQR1 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
SETD7 Q8WTS6 1/20 0.34
PIK3CA P42336 1/20 0.34
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
AKT3 Q9Y243 1/20 0.33
MAPK1 P28482 1/20 0.33
CA2 P00918 2/20 0.32
S100A4 P26447 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3550893 0.90 CDC25A (0.60) CDC25ACDC25BCDC25CMALT1CDK4
SCHEMBL3552795 0.88 CDC25A (0.60) CDC25ACDC25BCDC25CMALT1CDK4
SCHEMBL3547085 0.88 CDC25A (0.60) CDC25ACDC25BCDC25CMALT1CDK4
SCHEMBL3553331 0.88 CDC25A (0.60) CDC25ACDC25BCDC25CMALT1CDK4
SCHEMBL3546656 0.87 CDC25A (0.59) CDC25ACDC25BCDC25CMALT1CDK4
SCHEMBL3546951 0.87 CDC25A (0.62) CDC25ACDC25BCDC25CMALT1CDK4
SCHEMBL3542705 0.86 CDC25A (0.57) CDC25ACDC25BCDC25CMALT1CDK4
SCHEMBL3556224 0.85 CDC25A (0.56) CDC25ACDC25BCDC25CMALT1KMT2A
SCHEMBL2403315 0.85 CDC25A (0.59) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL3550436 0.84 CDC25A (0.58) CDC25ACDC25BCDC25CMALT1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317658-A1 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2010-12-16 US claimed
US-7795284-B2 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses IPSEN PHARMA S.A.S. (FR) 2010-09-14 US claimed
EP-1814879-B1 DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME SOD CONSEILS RECH APPLIC (FR) 2008-09-24 EP claimed
US-20070244186-A1 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2007-10-18 US claimed
US-20100317658-A1 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2010-12-16 US disclosed
US-7795284-B2 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses IPSEN PHARMA S.A.S. (FR) 2010-09-14 US disclosed
EP-1814879-B1 DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME SOD CONSEILS RECH APPLIC (FR) 2008-09-24 EP disclosed
US-20070244186-A1 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses IPSEN PHARMA S.A.S. (FR) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244186-A1 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885
US-20100317658-A1 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.